Reduction of Ischemia-reperfusion Injury to Skin Flap by Treatment with Monoclonal Antibody to Endothelial Leukocyte Adhesion Molecule-1

  • OHASHI Masakazu
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>
  • TOSA Yasuyoshi
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>
  • HOSAKA Yoshiaki
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>
  • SATOH Kaneshige
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>
  • OGUZ YENIDUNYA Mehmet
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>
  • PANG Baohua
    <I>Department of Plastic and Reconstructive Surgery, Showa University School of Medicine</I>

抄録

The selectin family, which mediates adhesion of activated leukocytes to the vascular endothelium, plays an important role in inflammation. Endothelial leukocyte adhesion molecule-1 (SLAM-1) is expressed on activated vascular endothelium and mediates the special leukocyte rolling phenomenon seen when leukocytes adhere to vascular endothelium. We investigated changes in skin flap survival / necrosis due to treatment with the monoclonal antibody (Mab) to ELAM-1. Twenty-five male Sprague-Dawley rats (225-250 g) were used in the experiment. A 45 × 30 mm pedicled skin flap with superficial epigastric vessels was designed in the right inguinal region and prepared. Animals in the treated group received anti-ELAM-1 Mab intravenously 15 minutes prior to reperfusion ; those in the control group received normal saline. By tracing the outline of viable and nonviable areas skin flap viability was assessed. Data were collected for the subsequent 7 days. These data corroborated with histological evidence on comparable areas of the flap. Tracing analysis revealed an average flap survival area of 91.7% in the treated group and 18.3% in the control group (P < 0.005) . Histopathologically, few inflammatory changes were observed in the treated group, while marked damage was observed in the control group. We conclude that treating skin flaps with anti-ELAM-1 was effective in reducing ischemia-reperfusion (I-R) injury after 9 hours of warm ischemia.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (18)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ